First-generation and second-generation Bruton tyrosine kinase inhibitors in Waldenström macroglobulinemia Journal Article

  


Authors: Argyropoulos, K. V.; Lia, M.
Article Title: First-generation and second-generation Bruton tyrosine kinase inhibitors in Waldenström macroglobulinemia
Abstract: Waldenström macroglobulinemia (WM) is an indolent B-cell lymphoma that is heavily dependent on Bruton tyrosine kinase (BTK) hyperactivation. Ibrutinib is a first-generation BTK inhibitor that has shown high activity and durable responses in patients with relapsed/refractory WM. Newer and more selective BTK inhibitors are currently being tested in several clinical trials and are expected to address the toxicity and the acquired resistance observed in patients receiving ibrutinib. Updates on ibrutinib and second-generation BTK inhibitors are summarized in this review. © 2018 Elsevier Inc.
Keywords: signal transduction; constipation; drug tolerability; neutropenia; review; placebo; dose response; drug safety; drug withdrawal; nonhuman; drug targeting; rituximab; bortezomib; proteasome inhibitor; mantle cell lymphoma; anemia; bleeding; thrombocytopenia; alkylating agent; nucleoside analog; herpes zoster; waldenstroem macroglobulinemia; antineoplastic activity; carcinogenesis; cancer resistance; monoclonal antibody; drug dose escalation; pneumonia; purpura; b cell lymphoma; dosage schedule comparison; urinary tract infection; single drug dose; immunomodulation; headache; drug bioavailability; maximum plasma concentration; drug absorption; drug half life; chronic lymphatic leukemia; hematoma; atrial fibrillation; upper respiratory tract infection; drug elimination; petechia; skin abscess; contusion; endocarditis; bruton tyrosine kinase; faintness; ibrutinib; human; priority journal; btk; ic50; venetoclax; daratumumab; second-generation btk inhibitors; waldenström macroglobulinemia; 2 cyano n (2,5 dibromophenyl) 3 hydroxycrotonamide; acalabrutinib; bruton tyrosine kinase inhibitor; sns 062; tirabrutinib; ulocuplumab; vecabrutinib; zanubrutinib; muscle hematoma
Journal Title: Hematology/Oncology Clinics of North America
Volume: 32
Issue: 5
ISSN: 0889-8588
Publisher: Elsevier Inc.  
Date Published: 2018-10-01
Start Page: 853
End Page: 864
Language: English
DOI: 10.1016/j.hoc.2018.05.012
PROVIDER: scopus
PUBMED: 30190023
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050117001&doi=10.1016%2fj.hoc.2018.05.012&partnerID=40&md5=8df9ffb4298c363f0af965a5224e8678
Notes: Review -- Export Date: 5 October 2018 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Maria Lia Palomba
    417 Palomba
  2. Kimon Argyropoulos
    44 Argyropoulos
Related MSK Work